[Uridine diphosphate glucose in acute viral hepatitis].
200 mg UDPG or placebo respectively were administered after an observation period of 1 week to two randomly constructed groups of patients aged 15-35 yr with acute viral hepatitis but no prior history of disease. In the treated patients, mean decreases were most marked and most rapid in the case of SGOT, SGPT, alkaline phosphatase and total bilirubinaemia. These results offer good reason for supposing that UDPG can be usefully employed in the management of acute viral hepatitis.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000469:Alkaline Phosphatase / Q000378:metabolism; D001663:Bilirubin / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006525:Hepatitis, Viral, Human / Q000188:drug therapy*; D006801:Humans; D008297:Male; D000637:Transaminases / Q000378:metabolism; D014532:Uridine Diphosphate Glucose / Q000627:therapeutic use*; D014539:Uridine Diphosphate Sugars / Q000627:therapeutic use*
D014539:Uridine Diphosphate Sugars; D000637:Transaminases; D000469:Alkaline Phosphatase; D001663:Bilirubin; D014532:Uridine Diphosphate Glucose
L'uridin-5'-difosfoglucosio in corso di epatite virale acuta.